Drug-Induced Long QT Syndrome in Injection Drug Users Receiving Methadone: High Frequency in Hospitalized Patients and Risk Factors | Cardiology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.238.77. Please contact the publisher to request reinstatement.
1.
Al-Khatib  SMLaPointe  NMKramer  JMCaliff  RM What clinicians should know about the QT interval.  JAMA 2003;2892120- 2127PubMedGoogle ScholarCrossref
2.
Roden  DM Drug-induced prolongation of the QT interval.  N Engl J Med 2004;3501013- 1022PubMedGoogle ScholarCrossref
3.
Shah  RR The significance of QT interval in drug development.  Br J Clin Pharmacol 2002;54188- 202PubMedGoogle ScholarCrossref
4.
Johnson  REChutuape  MAStrain  ECWalsh  SLStitzer  MLBigelow  GE A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.  N Engl J Med 2000;3431290- 1297PubMedGoogle ScholarCrossref
5.
Eap  CBBertschy  GBaumann  PFinkbeiner  TGastpar  MScherbaum  N High interindividual variability of methadone enantiomer blood levels to dose ratios.  Arch Gen Psychiatry 1998;5589- 90PubMedGoogle ScholarCrossref
6.
Leavitt  SBShinderman  MMaxwell  SEap  CBParis  P When “enough” is not enough: new perspectives on optimal methadone maintenance dose.  Mt Sinai J Med 2000;67404- 411PubMedGoogle Scholar
7.
Kornick  CAKilborn  MJSantiago-Palma  J  et al.  QTc interval prolongation associated with intravenous methadone.  Pain 2003;105499- 506PubMedGoogle ScholarCrossref
8.
Krantz  MJLewkowiez  LHays  HWoodroffe  MARobertson  ADMehler  PS Torsade de pointes associated with very-high-dose methadone.  Ann Intern Med 2002;137501- 504PubMedGoogle ScholarCrossref
9.
Gil  MSala  MAnguera  I  et al.  QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone.  Am J Cardiol 2003;92995- 997PubMedGoogle ScholarCrossref
10.
Martell  BAArnsten  JHRay  BGourevitch  MN The impact of methadone induction on cardiac conduction in opiate users.  Ann Intern Med 2003;139154- 155PubMedGoogle ScholarCrossref
11.
Martell  BAArnsten  JHKrantz  MJGourevitch  MN Impact of methadone treatment on cardiac repolarization and conduction in opioid users.  Am J Cardiol 2005;95915- 918PubMedGoogle ScholarCrossref
12.
Lipski  JStimmel  BDonoso  E The effect of heroin and multiple drug abuse on the electrocardiogram.  Am Heart J 1973;86663- 668PubMedGoogle ScholarCrossref
13.
Piguet  VDesmeules  JEhret  GStoller  RDayer  P QT interval prolongation in patients on methadone with concomitant drugs.  J Clin Psychopharmacol 2004;24446- 448PubMedGoogle ScholarCrossref
14.
Bittar  PPiguet  VKondo-Oestreicher  MDesmeules  JDayer  P Methadone induced long QTc and “torsade de pointes” [abstract P244].  Swiss Medical Forum 2002; ((April 10, suppl 8)) 36SGoogle Scholar
15.
Bazett  HC An analysis of the time-relations of electrocardiograms.  Heart 1920;7353- 370Google Scholar
16.
Morganroth  JBrown  AMCritz  S  et al.  Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event.  Am J Cardiol 1993;7226B- 31BPubMedGoogle ScholarCrossref
17.
Garson  A  Jr How to measure the QT interval–what is normal?  Am J Cardiol 1993;7214B- 16BPubMedGoogle ScholarCrossref
18.
Morganroth  J Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.  Am J Cardiol 1993;7210B- 13BPubMedGoogle ScholarCrossref
19.
Gault  MHLongerich  LLHarnett  JDWesolowski  C Predicting glomerular function from adjusted serum creatinine.  Nephron 1992;62249- 256PubMedGoogle ScholarCrossref
20.
Bonnabry  PSievering  JLeemann  TDayer  P Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies.  Clin Pharmacokinet 2001;40631- 640PubMedGoogle ScholarCrossref
21.
 QT Drug Lists [database online].  Tucson The University of Arizona Center for Education and Research on Therapeutics2003;http://www.torsades.org/medical-pros/drug-lists/drug-lists.htm. Accessed December 2003
22.
Moss  A Panel discussion.  Drug Saf 1999;21 ((suppl 1)) 81- 87PubMedGoogle ScholarCrossref
23.
Montanez  ARuskin  JNHebert  PRLamas  GAHennekens  CH Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies.  Arch Intern Med 2004;164943- 948PubMedGoogle ScholarCrossref
24.
Ray  WAMurray  KTMeredith  SNarasimhulu  SSHall  KStein  CM Oral erythromycin and the risk of sudden death from cardiac causes.  N Engl J Med 2004;3511089- 1096PubMedGoogle ScholarCrossref
25.
Tegeder  ILotsch  JGeisslinger  G Pharmacokinetics of opioids in liver disease.  Clin Pharmacokinet 1999;3717- 40PubMedGoogle ScholarCrossref
26.
Moody  DEWalsh  SLRollins  DENeff  JAHuang  W Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.  Clin Pharmacol Ther 2004;76154- 166PubMedGoogle ScholarCrossref
27.
Makkar  RRFromm  BSSteinman  RTMeissner  MDLehmann  MH Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.  JAMA 1993;2702590- 2597PubMedGoogle ScholarCrossref
28.
Joseph  HStancliff  SLangrod  J Methadone maintenance treatment (MMT): a review of historical and clinical issues.  Mt Sinai J Med 2000;67347- 364PubMedGoogle Scholar
29.
 Center for Substance Abuse Treatment, Methadone-Associated Mortality: Background Briefing Report.  Rockville, Md Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration2004;
30.
Pearson  ECWoosley  RL QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.  Pharmacoepidemiol Drug Saf 2005;14747- 753PubMedGoogle ScholarCrossref
31.
Maremmani  IPacini  MCesaroni  CLovrecic  MPerugi  GTagliamonte  A QTc interval prolongation in patients on long-term methadone maintenance therapy.  Eur Addict Res 2005;1144- 49PubMedGoogle ScholarCrossref
32.
Lucchini  ABarbaro  GBarbarini  G Methadone and QT prolongation in HIV-infected patients.  Am J Cardiol 2004;94147- 148PubMedGoogle ScholarCrossref
33.
O'Leary  ME Inhibition of HERG potassium channels by cocaethylene: a metabolite of cocaine and ethanol.  Cardiovasc Res 2002;5359- 67PubMedGoogle ScholarCrossref
34.
Krantz  MJGarcia  JAMehler  PS Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes.  Pharmacotherapy 2005;25611- 614PubMedGoogle ScholarCrossref
Original Investigation
June 26, 2006

Drug-Induced Long QT Syndrome in Injection Drug Users Receiving Methadone: High Frequency in Hospitalized Patients and Risk Factors

Author Affiliations

Author Affiliations: Divisions of Clinical Pharmacology and Toxicology (Drs Ehret, Voide, Chabert, Piguet, Dayer, and Desmeules), General Internal Medicine (Drs Ehret, Gaspoz, and Perrier), and Cardiology (Dr Shah) and Departments of Psychiatry, Clinical Research Unit (Dr Gex-Fabry) and Community Health (Dr Broers and Mr Musset), Geneva University Hospital, Geneva, Switzerland. Dr Ehret is currently with the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.

Arch Intern Med. 2006;166(12):1280-1287. doi:10.1001/archinte.166.12.1280
Abstract

Background  Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.

Methods  We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.

Results  Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second½ or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P<.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.

Conclusions  QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone.

×